Ranbaxy Settles With GSK Over Generic Migraine Drug

Law360, New York (January 22, 2008, 12:00 AM EST) -- Ranbaxy Laboratories Ltd. said it has reached a settlement with GlaxoSmithKline Plc, putting a stop to any possible patent litigation over a generic version of GSK's migraine drug Imitrex.

Under the settlement, the India-based drugmaker will be able to distribute a generic version of sumatriptan succinate tablets, which are sold under the brand name Imitrex. Ranbaxy says it expects to market the generic migraine medication in December 2008.

GlaxoSmithKline's patent covering Imitrex is set to expire in February 2009.

Ranbaxy will be able to distribute tablets...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.